Clinical Trials Logo

Clinical Trial Summary

This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05988073
Study type Observational
Source argenx
Contact Sabine Coppieters, MD
Phone 857-350-4834
Email ClinicalTrials@argenx.com
Status Recruiting
Phase
Start date November 29, 2023
Completion date November 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06040567 - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Not yet recruiting NCT02885259 - HyQvia in Multifocal Motor Neuropathy N/A
Active, not recruiting NCT01655394 - Change of Nerve Conduction Properties in IVIg Dependent Neuropathies N/A
Active, not recruiting NCT05225675 - A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy Phase 2
Completed NCT02556437 - Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) Phase 2
Completed NCT02111590 - Immunoglobulin Dosage and Administration Form in CIDP and MMN N/A
Completed NCT00666263 - Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy Phase 3
Completed NCT00268788 - Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy Phase 2
Completed NCT02121678 - Effect of Resistance and Aerobic Exercise in CIDP or MMN N/A
Completed NCT01827072 - Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. Phase 3